Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News MediciNova Inc MNOV

Healthcare Biotechnology
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple... see more

Current News (NDAQ:MNOV)

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

GlobeNewswire 8 days ago

2026 New Year's Greetings from the CEO

GlobeNewswire January 6, 2026

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

GlobeNewswire December 18, 2025

MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

GlobeNewswire December 8, 2025

Message from the CEO to MediciNova Shareholders

GlobeNewswire December 1, 2025

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

GlobeNewswire November 18, 2025

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

GlobeNewswire November 6, 2025

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

GlobeNewswire November 4, 2025

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

GlobeNewswire October 30, 2025
View More News ››

Opinion & Analysis (NDAQ:MNOV)

MediciNova Shares Rise 40% on Plans to Initiate COVID-19 ARDS Clinical Trial

Streetwise Reports April 13, 2020
View More Opinion ››

Bullboard Posts (NDAQ:MNOV)

Using technical analysis for this stock.

It is starting a new uptrend for shareholders today,so good luck to all of you guys
coolfooldumbguy - October 31, 2025
View more Bullboard ››

G Mining Ventures Corp.

G Mining Ventures Corp.

G Mining Ventures Corp., a mining company, engages in the acquisition, exploration, and development of precious metal ...
View More »

Podcasts